UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042745
Receipt number R000048765
Scientific Title Effect of Daily Ingestion of Test Food on Improving Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study
Date of disclosure of the study information 2020/12/18
Last modified on 2021/04/15 13:52:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of Daily Ingestion of Test Food on Improving Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study

Acronym

Beneficial Effects of Test Food on Improving Gut Microbiota

Scientific Title

Effect of Daily Ingestion of Test Food on Improving Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study

Scientific Title:Acronym

Beneficial Effects of Test Food on Improving Gut Microbiota

Region

Japan


Condition

Condition

Healthy Adult

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate clinical benefits associated with 4 weeks daily ingestion of the test food on improving gut microbiota in a randomized, double-blind, placebo-controlled, parallel group study.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase



Assessment

Primary outcomes

Defecation frequency and gut microbiota at 4 weeks after beginning the intake of test food.

Key secondary outcomes

Bowel diary, Heart rate variability, VAS questionnaire on stress, electroencephalogram during sleeping, sleeping record


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Daily ingestion 180 g of test food (low dose) for 4 weeks.

Interventions/Control_2

Daily ingestion 180 g of test food (high dose) for 4 weeks.

Interventions/Control_3

Daily ingestion 180 g of placebo food for 4 weeks.

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

60 years-old >

Gender

Male and Female

Key inclusion criteria

1. Subjects who agree to participate in this study with a written informed consent.
2. Subjects who are aware of having a tendency toward constipation.
3. Subjects with defecation frequency less than 5 times per week.

Key exclusion criteria

1. Subjects with a clinical history of gastrointestinal cancer or currently under treatment or anti-tumor medication.
2. Subjects with gastrointestinal disorders such as inflammatory bowel syndrome, irritable bowel syndrome, etc.
3. Subjects who may cause some skin troubles by measuring electroencephalogram and/or heart rate variability.
4. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities.
5. Subjects who take digoxin.
6. Subjects with major surgical history relevant to the digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc.
7. Subjects with unusually high and/or low blood pressure and/or abnormal hematological data.
8. Subjects with severe anemia.
9. Pre- or post-menopausal women complaining of obvious physical changes.
10. Subjects who are at risk of having allergic reactions to drugs or foods especially based on wheat, milk, and egg.
11. Subjects who regularly take drugs, functional foods and/or supplements which potentially affect bowel movements and/or gut microbiota.
12. Subjects who regularly take staple food with high dietary fiber.
13. Subjects who regularly take yoghurt, lactic acid bacteria beverage, and natto.
14. Heavy smokers, alcohol addicts or subjects with disordered lifestyle.
15. Subjects who have used antibiotics within 12 weeks prior to the current study.
16. Subjects who donated either 400 ml whole blood within 16 weeks (women), 12 weeks (men), 200 ml whole blood within 4 weeks, or blood components within 2 weeks, prior to the current study.
17. Pregnant or lactating women or women who expect to be pregnant during this study.
18. Subjects who currently participate in other clinical trials, or participated within the last 4 weeks prior to the current study.
19. Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator.

Target sample size

24


Research contact person

Name of lead principal investigator

1st name Jun
Middle name
Last name NISHIHIRA

Organization

Hokkaido Information University

Division name

Department of Medical Management and Informatics

Zip code

069-8585

Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

TEL

011-385-4411

Email

nishihira@do-johodai.ac.jp


Public contact

Name of contact person

1st name Jun
Middle name
Last name NISHIHIRA

Organization

Hokkaido Information University

Division name

Health Information Science Center

Zip code

069-8585

Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

TEL

011-385-4430

Homepage URL


Email

nishihira@do-johodai.ac.jp


Sponsor or person

Institute

Hokkaido Information University

Institute

Department

Personal name



Funding Source

Organization

National Agriculture and Food Research Organization, bio-oriented technology Research Advancement Institution

Organization

Division

Category of Funding Organization

Government offices of other countries

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

National Agriculture and Food Research Organization

Name of secondary funder(s)

Nisshin Seifun Group Inc.


IRB Contact (For public release)

Organization

The ethics committee of Hokkaido Information University

Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

Tel

011-385-4411

Email

soumu@do-johodai.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

北海道情報大学 保健センター(北海道)


Other administrative information

Date of disclosure of the study information

2020 Year 12 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 11 Month 25 Day

Date of IRB

2020 Year 11 Month 25 Day

Anticipated trial start date

2021 Year 01 Month 14 Day

Last follow-up date

2021 Year 03 Month 26 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 12 Month 14 Day

Last modified on

2021 Year 04 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048765


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name